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Cellular senescence is thought to be an important tumor suppression process in vivo. We have pre-
viously shown that p53 activation is necessary for CKII inhibition-mediated cellular senescence.
Here, CKII inhibition induced acetylation of p53 at K382 in HCT116 and HEK293 cells. This acetyla-
tion event was suppressed by SIRT1 activation. CKIIa and CKIIb were co-immunoprecipitated with
SIRT1 in a p53-independent manner. Maltose binding protein pull-down and yeast two-hybrid indi-
cated that SIRT1 bound to CKIIb, but not to CKIIa. CKII inhibition reduced SIRT1 activity in cells. CKII
phosphorylated and activated human SIRT1 in vitro. Finally, SIRT1 overexpression antagonized CKII
inhibition-mediated cellular senescence. These results reveal that CKII downregulation induces p53
stabilization by negatively regulating SIRT1 deacetylase activity during senescence.
Structured summary of protein interactions:
CKII Beta binds to SIRT1 by pull down (View interaction)
CKII Beta physically interacts with SIRT1 by pull down (View interaction)
SIRT1 physically interacts with CKII Beta and CKII Alpha by anti bait coimmunoprecipitation (View
Interaction: 1, 2, 3)
CKII Beta physically interacts with SIRT1 by two hybrid (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Normal primary cells withdraw from the cell division cycle after
a ﬁnite number of divisions and enter irreversible growth arrest
designated as replicative senescence, or more generally, cellular
senescence [1]. Cellular senescence can also be induced by oxida-
tive stress, DNA damage, and oncogenic activation [2–6]. Senes-
cence is thought to be an important tumor suppression process
in vivo. In a state of senescence, cells become enlarged, acquire a
ﬂattened shape, and express several senescence-associated mark-
ers such as senescent-associated b-galactosidase (SA-b-gal),
cyclin-dependent kinase inhibitor p21Cip1/WAF1, and tumor sup-
pressor protein p53 [7–10]. p53 is a transcription factor that playschemical Societies. Published by E
wn as casein kinase II); DRB,
C, histone deacetylase; MBP,
, phosphate-buffered saline;
ociated b-galactosidase; Sir2,
ulfonyl ﬂuoride; SDS, sodiuma major role in cell cycle regulation. It is activated in response to a
variety of cellular stress signals, where upon it triggers cell cycle
arrest or apoptosis depending on the circumstances. p53 activity
is modulated by protein stability and post-translational modiﬁca-
tions, including phosphorylation and acetylation [11].
The silent information regulator 2 (Sir2) is an NAD-dependent
protein deacetylase that controls longevity in lower eukaryotes,
such as budding yeast and nematode [12,13]. An increase in Sir2
activity extends the lifespan of these organisms. Mammals possess
seven paralogs of the Sir2 gene, with SIRT1 being the most similar
to Sir2. SIRT1 deacetylates not only histones (H1, H3, and H4),
but also many non-histone proteins such as p53 [14]. It has
been shown that SIRT1 is also important for various cellular
functions, including apoptosis, differentiation, proliferation, and
metabolism.
Protein kinase CKII (formerly known as casein kinase II) (CKII),
a ubiquitous serine/threonine kinase, plays a signiﬁcant role in
the control of cell proliferation and transformation [15–17]. The
holoenzyme of CKII is a heterotetramer composed of two cata-
lytic (a and/or a0) and two regulatory (b) subunits. We previously
demonstrated that CKII activity is downregulated at the tran-
scriptional level in both senescent human lung ﬁbroblastlsevier B.V. All rights reserved.
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tors or CKIIa small-interfering RNA (siRNA) induces premature
senescence in IMR-90 cells [18]. In addition, silencing of the CKIIa
and CKIIa0 genes during cellular senescence is mediated by DNA
methylation [19]. Studies designed to examine the mechanism
through which CKII inhibition contributes to the development
of senescence have indicated that p53 is involved in the develop-
ment of senescence induced by CKII inhibition in HCT116 human
colon cancer cells [20]. Superoxide anion generation by NADPH
oxidase (NOX) activation is the upstream mediator of p53
stabilization in cells made senescent by CKII inhibition [21].
However, we cannot rule out the possibility that CKII downregu-
lation also mediates p53 stabilization by another mechanism.
Here, we provide evidence that CKII downregulation can stabilize
p53 via inhibition of SIRT1 deacetylase activity in cells and that,
conversely, exogenous SIRT1 delays CKII inhibition-mediated
senescence.2. Materials and methods
2.1. Cell culture and transfection
Human colon cancer HCT116 and human embryonic kidney
(HEK) 293 cells were grown in Dulbecco’s modiﬁed Eagle’s med-
ium (DMEM) supplemented with 10% fetal bovine serum at 37 C
in 5% CO2. To establish SIRT1-overexpressing cells, cells were
transfected with pECE-Flag-SIRT1 by Lipofectamine (Invitrogen,
Carlsbad, CA) as described by the manufacturer.
2.2. Preparation of cell extracts
For Western blotting, cells in 100-mm dishes were washed with
ice-cold phosphate-buffered saline (PBS), collected by scraping
with a rubber policeman, and lysed in 100 ll of ice-cold RIPA buf-
fer [50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 0.5 mM
phenylmethylsulfonyl ﬂuoride (PMSF), 1 lg/ml of aprotinin, 1 lg/
ml of leupeptin, and 1 lg/ml of pepstatin]. For measurement of
deacetylase activity, cells were lysed by sonication in lysis buffer
[50 mM Tris–HCl (pH 8.0), 20 mM NaCl, 1 mM MgCl2, 1 mM EDTA,
1% Nonidet P-40, 0.5 mM PMSF, 1 lg/ml of aprotinin, 1 lg/ml of
leupeptin, 1 lg/ml of pepstatin, 1 mM sodium orthovanadate,
1 mM sodium pyrophosphate, and 4 mM p-nitrophenyl phos-
phate]. The particulate debris was then removed by centrifugation
at 12000g. The volumes of the supernatants were adjusted for
equal protein concentration.
2.3. Immuno-blotting
Proteins were separated by polyacrylamide gel electrophore-
sis in the presence of SDS and then transferred by electrophore-
sis to a nitrocellulose membrane. The membrane was blocked
with 5% (w/v) non-fat, dry skim milk in TBST [20 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 0.05% Tween 20] for 2 h and then incu-
bated with speciﬁc antibodies in 1% (w/v) non-fat, dry skim milk
for 1 h. The membrane was washed three times in TBST and
then analyzed with the ECL system (Amersham Pharmacia Bio-
tech, Korea). Some membranes were stripped in stripping buffer
[2% SDS, 100 mM b-mercaptoethanol, and 50 mM Tris–HCl
(pH 7.0)] at 50 C for 1 h with gentle shaking and then reprobed
with anti-b-actin antibody as a control for protein loading. Anti-
p53, -CKIIa, -SIRT1, and -b-actin antibodies were obtained from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Anti-acetyl p53
K382 antibody was obtained from Cell Signaling Technology
(Danvers, MA).2.4. Maltose binding protein (MBP) pull-down assay and
immunoprecipitation
AnMBP pull-down assaywas performed by incubating amylose-
agarose beads with MBP-CKII and cell lysates in 200 ll of binding
buffer [20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM PMSF]. The
reaction was allowed to proceed for 1 h while rocking at 4 C. For
immunoprecipitation, cell lysates were pre-cleared with normal
mouse or rabbit IgG along with protein A Sepharose (Amersham
Biosciences, Piscataway, NJ) for 1 h at 4 C. The supernatant was
then incubated with anti-CKII or anti-SIRT1 antibody along with
protein A Sepharose with mixing for 12 h at 4 C. The beads were
collected by centrifugation and washed three times with PBS.
2.5. Yeast two-hybrid assay
The reporter strain Saccharomyces cerevisiae HF7c (MATa ura3-
52 his3-200 ade2-101 lys2-801 trpl-901 leu2-3112 gal4-542 gal80-
538 LYS2::GAL1UAS-GAL1TATA-HIS3 URA3::GAL417mers(x3)-CyC1TA-
TA-lacZ) was co-transformed with various combinations of hybrid
plasmids containing a DNA-binding domain or a transcriptional
activation domain. Transformants were plated on synthetic med-
ium lacking tryptophan and leucine. After 4 days of growth, the
transformants were cultured on selective medium lacking trypto-
phan, leucine, and histidine but including 1 mM 3-amino-triazole,
after which they were incubated for 4 days at 30 C. Interactions
between the hybrid proteins were monitored by growth on selec-
tive media.
2.6. RNA interference
The siRNA for CKIIa was 50-UCAAGAUGACUACCAGCUGdTdT.
The siRNA for the negative control was 50-GCUCAGAUCAAUACG-
GAGAdTdT. Both siRNAs were transfected into cells using Lipofect-
amine (Invitrogen) as described by the manufacturer. Five hours
after transfection, the medium was changed, and the cells were
grown for another 3 days before being harvested or stained for
SA-b-gal.
2.7. Puriﬁcation of CKII and SIRT1 phosphorylation by CKII
CKII holoenzyme and CKII subunits tagged with MBP were ex-
pressed in Escherichia coli and puriﬁed as described previously
[22,23]. Phosphorylation of human SIRT1 (BIOMOL International,
Plymouth Meeting, PA) by CKII was carried out in a reaction mix-
ture containing 20 mM Tris–HCl (pH 7.5), 100 mM KCl, 10 mM
MgCl2, 1 mM DTT, 1 mM EGTA, 100 lM [c-32P]ATP, and 1 lg of hu-
man SIRT1 in a total volume of 30 ll. The reactions were initiated
by the addition of puriﬁed CKII and incubated for 15 min at 30 C.
The samples were then separated on a 10% SDS–polyacrylamide
gel. The gel was stained with Coomassie blue, dried, and subjected
to autoradiography.
2.8. Measurement of histone deacetylase (HDAC) and SIRT1 activity
HDAC activity was assessed with the HDAC Colorimetric Assay/
Drug Discovery Kit (BIOMOL International) according to the manu-
facturer’s instructions. Brieﬂy, cell extracts and Color de Lys™ sub-
strate were added to the wells of a microtiter plate and incubated
at 37 C for 15 min. HDAC inhibitor trichostatin A and Color de
Lys™ developer were added to stop the HDAC reaction. The mix-
ture was incubated at 37 C for 10 min and read on a microtiter-
plate reader (PerkinElmer, Waltham, MA) at 405 nm. The enzyme
activity of SIRT1 was measured with the SIRT1 Fluorimetric Drug
Discovery Kit (BIOMOL International) based on Fluor de Lys–SIRT1
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The deacetylase activity was detected as a ﬂuorescent emission at
460 nmwith an excitation wavelength of 355 nm. The ﬂuorescence
intensity of the compounds at 460 nm was subtracted from the
values measured in the assay. The resulting value was treated as
the baseline value in the absence of compound. The experiments
were performed at least three times.
2.9. SA-b-gal activity assay
SA-b-gal activity was measured as described previously [8] with
minor modiﬁcations. Cells in sub-conﬂuent cultures were washed
with PBS, ﬁxed in 3% (v/v) formaldehyde in PBS for 10 min at room
temperature, and then incubated with a stain solution containing
1 mg/ml of 5-bromo-4-chloro-3-indolyl b-D-galactoside, 40 mM
citric acid-sodium phosphate (pH 6.0), 5 mM potassium ferricya-
nide, 5 mM potassium ferrocyanide, 150 mM NaCl, and 2 mM
MgCl2 for 24 h at 37 C. The number of blue-stained cells was
counted in at least 10 ﬁelds at 400 magniﬁcation and expressed
as percentage of positive cells.
2.10. Growth curves
Cells were seeded in six-well dishes at a starting density of
5000 cells/well with duplicate wells for each sample. Every 24 h,
cells were trypsinized and counted in triplicate using a hemocy-
tometer. Trypan blue was used to distinguish viable cells from
non-viable cells.
2.11. Statistical analysis
Results are presented as the means ± standard errors. Statistical
analysis was performed with SPSS version 11.0 (SPSS Inc., Chicago,
IL). Data were analyzed by one-way ANOVA, and Duncan’s multi-Fig. 1. CKII inhibition induces SIRT1-dependent p53 K382 acetylation. HCT116 (A, B, D,
6 days (A–D), or transfected with CKIIa siRNA for 4 days (E) in the presence or absenc
treatment with resveratrol. Cells were treated with resveratrol (10 lM) for 0–6 days in th
for 3 days. Cells were lysed and subjected to electrophoresis on a 10% (w/v) SDS–polyacr
acetyl-K382 p53, anti-SIRT1, anti-CKIIa, and anti-b-actin antibodies.ple-range test was performed if differences were identiﬁed among
the groups at P < 0.05. Analysis between two groups was deter-
mined by using unpaired Student’s t-test.
3. Results and discussion
3.1. SIRT1-dependent p53 K382 deacetylation decreases during CKII
inhibition-mediated senescence
We previously demonstrated that CKII inhibition induces cellu-
lar senescence through the p53-dependent pathway in HCT116
cells [20]. SIRT1 has been shown to be involved in cellular senes-
cence [12,13] and regulate p53 K382 acetylation [14]. To examine
whether or not p53 K382 acetylation contributes to CKII inhibi-
tion-induced p53 stabilization in senescent cells, we treated
HCT116 cells with CKII inhibitors, apigenin and 5,6-dichloro-1-b-
D-ribofuranosylbenzimidazole (DRB), and then determined the
protein level and acetylation status of p53 by immuno-blotting.
As shown in Fig. 1A, expression of p53 was upregulated in apige-
nin- or DRB-treated HCT116 cells. In addition, acetylation of p53
K382 was induced by treatment with CKII inhibitors. To determine
if SIRT1 activity blocks CKII inhibition-induced p53 K382 acetyla-
tion, we added the SIRT1 activator resveratrol to HCT116 cells in
the presence of CKII inhibitor. Apigenin-induced acetylation of
p53 K382 was inhibited by resveratrol, indicating that SIRT1 re-
duced p53 acetylation during CKII inhibition-induced senescence
(Fig. 1B). The apigenin-induced acetylation of p53 K382 was also
inhibited by resveratrol in HEK293 cells (Fig. 1C). However, the
protein levels of SIRT1 were unchanged in these cells, indicating
that SIRT1 deacetylase activity was regulated by post-translational
modiﬁcation (Fig. 1A and C). We performed time-course studies
and found that treatment of cells with resveratrol (2 lM) de-
creased p53 K382 acetylation levels within 2 days (Fig. 1D). To
conﬁrm the role of resveratrol in p53 K382 acetylation inducedand E) and HEK293 (C) cells were treated with CKII inhibitors, apigenin or DRB for
e of the SIRT1 activator resveratrol. (D) Time course of p53 K382 acetylation after
e presence of apigenin. (F) HCT116 cells were treated with DRB and pECE-Flag-SIRT1
ylamide gel. Protein bands were visualized by immunoblotting with anti-p53, anti-
Fig. 2. CKIIb subunit interacts with SIRT1. (A) Cell lysates from HCT116 cells were subjected to immunoprecipitation (IP) with anti-SIRT1, anti-CKIIa, and anti-CKIIb
antibodies, or normal rabbit IgG. The precipitated proteins were separated by 10% (w/v) SDS–polyacrylamide gel electrophoresis and visualized by Western blotting with
appropriate antibodies. (B) Puriﬁed human SIRT1 was incubated with MBP-CKII subunit-coated amylose resin. Precipitation with MBP-coated amylose resin was used as a
negative control. The immobilized complexes were recovered with 20 mM maltose and analyzed by Western blotting. (C) The reporter strain was co-transformed with
pGADGH-SIRT1 and pGBT9-CKIIa or pGBT9-CKIIb. Double transformants grew on non-selective medium lacking tryptophan and leucine (TL) and on selective medium
lacking tryptophan, leucine, and histidine (THL) but including 1 mM 3-amino-triazole. Interactions between the hybrid proteins were tested to assess the ability to support
growth on selective medium. (D) SIRT1 was precipitated from lysates of wild-type (WT) and p53/ HCT116 cells with MBP-CKII subunit-coated amylose resin. The
immobilized complexes were recovered with 20 mM maltose and analyzed by Western blotting.
Fig. 3. CKII phosphorylates and activates SIRT1. HCT116 cells were treated with CKII inhibitors for 6 days (A, B) or transfected with CKIIa siRNA for 4 days (C) in the presence
or absence of resveratrol. SIRT1 activity was measured in cell lysates as described in Section 2. Data are shown as the means ± S.E.M. ⁄P < 0.05. Bars that do not share a
common letter (a, b, c) are signiﬁcantly different among the groups at P < 0.05. (D) Human SIRT1 was incubated without (lane 1) or with (lane 2) CKII holoenzyme in the
presence of [c-32P]ATP and analyzed by SDS–polyacrylamide gel electrophoresis, with Coomassie Blue staining (CBB, left panel), autoradiography (middle panel), andWestern
blotting with anti-SIRT1 antibody (right panel). (E) The puriﬁed SIRT1 was incubated without or with CKII holoenzyme in the presence of ATP. Then, SIRT1 activity was
assayed as described in Section 2. Data are shown as the means ± S.E.M. ⁄P < 0.05.
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3364 S.Y. Jang et al. / FEBS Letters 585 (2011) 3360–3366by CKII downregulation, we knocked down CKIIa in HCT116 cells
by gene silencing using siRNA. Treatment of cells with CKIIa siRNA
stimulated acetylation of p53 at K382, and resveratrol suppressed
this acetylation event (Fig. 1E). To examine whether or not overex-
pression of SIRT1 affects CKII inhibition-induced p53 K382 acetyla-
tion, we transfected HCT116 cells with pECE-Flag-SIRT1. As shown
in Fig. 1F, exogenous expression of wild-type SIRT1, but not the
catalytically inactive mutant of SIRT1 (H363Y), suppressed CKII
inhibition-induced p53 K382 acetylation. Taken together, these re-
sults demonstrate that CKII inhibition can promote acetylation ofFig. 4. SIRT1 overexpression suppresses CKII inhibition-mediated senescence. HCT116
2 days. Cells were lysed and subjected to electrophoresis on a 10% (w/v) SDS–polyacryl
SIRT1, and anti-b-actin antibodies (upper panels). Cells were ﬁxed and stained with 5-bro
was measured. Representative images were obtained at 20magniﬁcation (bottom pane
b, c) are signiﬁcantly different among the groups at P < 0.05. (C) HCT116 cells that were
Every 24 h, cells were trypsinized and counted. These experiments were performed twice
cellular senescence. CKII downregulation generates ROS by activating NADPH oxidase [
results in activation of the p53-p21Cip1/WAF1-Rb-dependent cellular senescence pathwayp53 K382 through downregulation of SIRT1 deacetylase activity
in cells.
3.2. SIRT1 interacts with CKII through direct binding to CKIIb subunit
To determine whether or not SIRT1 is associated with CKII in
HCT116 cells, we immunoprecipitated SIRT1 and CKII from
HCT116 cell extracts. Normal IgG immunoprecipitation was used
as a control. As shown in Fig. 2A, both CKIIa and CKIIb were co-
precipitated with SIRT1. SIRT1 was also co-precipitated with CKIIa(A) and HEK293 (B) cells were treated with CKIIa siRNA and pECE-Flag-SIRT1 for
amide gel. Protein bands were visualized by immunoblotting with anti-CKIIa, anti-
mo-4-chloro-3-indolyl b-D-galactoside, and the percentage of positively stained cells
ls). Data are shown as the means ± S.E.M. Bars that do not share a common letter (a,
transfected with CKIIa siRNA and pECE-Flag-SIRT1 were seeded in six-well dishes.
with similar results. (D) Possible model illustrating CKII downregulation-mediated
21] and also inhibits SIRT1 deacetylase, leading to acetylation of p53. This process
[20]. ROS, reactive oxygen species; CDK, cyclin-dependent kinase.
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HCT116 cells. Next, to examine which subunit of CKII bound
directly to SIRT1, we puriﬁed MBP-CKIIa and MBP-CKIIb and tested
their ability to form a complex with SIRT1. When MBP-CKII sub-
units were mixed with puriﬁed human SIRT1, SIRT1 bound only
to MBP-CKIIb and not to CKIIa (Fig. 2B). The yeast two-hybrid sys-
tem conﬁrmed this ﬁnding (Fig. 2C). p53 has already been shown
to interact with SIRT1 [14] and CKIIb [24]. To examine whether
or not interaction of SIRT1 with CKII is p53-dependent, we used
p53/ HCT116 cells in which the p53 gene was inactivated by
homozygous knockout. When MBP pull-down assay was carried
out with p53/ cell extracts, SIRT1 was able to bind to CKIIb
regardless of p53 protein, indicating that the interaction between
CKII and SIRT1 was p53-independent (Fig. 2D). Taken together,
these results suggest that SIRT1 binds to CKIIb independently of
p53.
3.3. CKII stimulates SIRT1 deacetylase activity by phosphorylation
The ﬁnding that CKII inhibition-mediated acetylation of p53
K382 was inhibited by a SIRT1 activator suggested that CKII down-
regulation might inhibit the activity of SIRT1. To investigate this
possibility, we examined the effects of CKII inhibition on SIRT1
activity. Treatment with CKII inhibitors or CKIIa siRNA caused a
decrease in SIRT1 activity in HCT116 cells, but SIRT1 activity was
almost completely recovered in the presence of resveratrol
(Fig. 3A–C). Since the CKIIb subunit is known to determine sub-
strate speciﬁcity [15–17], we examined whether or not CKII cata-
lyzes the phosphorylation of SIRT1. Puriﬁed human SIRT1
became phosphorylated when incubated with CKII holoenzyme
in the presence of [c-32P]ATP. Phosphorylation of SIRT1 was not
observed when CKII was omitted from the reaction mixture, indi-
cating that SIRT1 was not autophosphorylated (Fig. 3D). To exam-
ine whether or not CKII modulates human SIRT1 deacetylase
activity in vitro, we assessed the activity of SIRT1 after preincuba-
tion with or without CKII in the presence of ATP. As shown in
Fig. 3E, preincubation with CKII stimulated human SIRT1 activity,
indicating that CKII phosphorylation was involved in the upregula-
tion of SIRT1 activity. Consistent with this ﬁnding, it was recently
reported that CKII phosphorylates mouse SIRT1 and regulates its
deacetylase activity [25].
HDAC1 is also known to catalyze the deacetylation of p53 K382
[26]. To examine whether or not CKII downregulation inhibits the
activity of HDAC1, we determined the effect of CKII inhibition on
HDAC1 activity in HCT116 cells. CKIIa siRNA treatment actually re-
sulted in stimulation of HDAC activity, suggesting that HDAC1 did
not affect the acetylation of p53 K382 in cells made senescent by
CKII inhibition (data not shown). Taken together, these results sug-
gest that CKII phosphorylates and activates human SIRT1 and that
CKII downregulation leads to a reduction in SIRT1 deacetylase
activity in cells.
3.4. SIRT1 overexpression suppresses CKII inhibition-mediated
senescence
We next examined whether or not SIRT1 antagonizes the cellu-
lar senescence induced by CKII inhibition. To detect senescence,
HCT116 cells were transfected with CKIIa siRNA and then stained
for SA-b-gal activity. There was a signiﬁcant increase in SA-b-gal
activity in response to CKIIa knock-down. However, co-transfec-
tion of these cells with wild-type SIRT1 resulted in a decrease in
the rate of SA-b-gal staining. In contrast, overexpression of the cat-
alytically inactive mutant of SIRT1 (H363Y) did not affect SA-b-gal
activity in the cells (Fig. 4A). Similar results were obtained with
HEK293 cells (Fig. 4B). To conﬁrm this ﬁnding, we generated
growth curves with HCT116 cells. As expected, CKIIa siRNA treat-ment decreased HCT116 cell proliferation. This reduction in prolif-
eration was reversed by expression of wild-type SIRT1 but not by
mutant SIRT1 H363Y (Fig. 4C).
We previously showed that the activated p53–p21Cip1/WAF1 path-
way acts as a mediator of CKII inhibition-induced cellular senes-
cence [20]. Stress signals, such as reactive oxygen species (ROS),
ionizing radiation, and DNA damage, converge on p53 and activate
CBP/p300 acetyltransferase, which acetylates p53 in the C-terminal
domain where K382 is located [11,27]. Recently, we revealed that
NOX-dependent superoxide anion production is an upstream con-
tributor to the CKII downregulation-mediated senescence signaling
cascade [21]. Here, we presented an additional mechanism for p53
stabilization during CKII downregulation-mediated senescence. The
present results indicate that CKII inhibition stimulates p53 stability
by negatively regulating SIRT1 deacetylase activity and that CKII
inhibition-mediated senescence can be antagonized by SIRT1 over-
expression. Therefore, based on previous ﬁndings and the current
study, we can conclude that through NOX activation, CKII inhibition
generates ROS that activate CBP/p300 acetyltransferases, which, in
turn, acetylate p53 K382. Furthermore, through downregulation of
SIRT1 deacetylase activity, CKII inhibition maintained the p53 acet-
ylation state, which is required for p53 activation during cellular
senescence (Fig. 4D). Cellular senescence is thought to be an impor-
tant tumor suppression process in vivo. Our results illustrate the po-
tential of targeting pathways involved in the regulation of p53 for
therapeutic use in various tumors.
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